RON alternative splicing regulation in primary ovarian cancer

Mayer,Sebastian; Hirschfeld,Marc; Jaeger,Markus; Pies,Susanne; Iborra,Severine; Erbes,Thalia; Stickeler,Elmar

doi:10.3892/or.2015.3995

RON alternative splicing regulation in primary ovarian cancer

Authors:
- Sebastian Mayer
- Marc Hirschfeld
- Markus Jaeger
- Susanne Pies
- Severine Iborra
- Thalia Erbes
- Elmar Stickeler
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, University Medical Center Freiburg, Freiburg, Germany
Published online on: May 19, 2015 https://doi.org/10.3892/or.2015.3995
Pages: 423-430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The proto-oncogene recepteur d'origine nantais (RON, MST1R) and its alternatively spliced variants are involved in various tumor biological processes, such as cell motility, adhesion, proliferation, apoptosis and epithelial-to-mesenchymal transition (EMT). RON overexpression and the occurrence of specific alternatively spliced RON isoforms have been detected in ovarian cancer. In the present study, we evaluated the role and regulation of cancer-related RON splicing isoforms in primary ovarian cancer. Expression of RON variants (RONΔ165, RONΔ160) was determined in 45 primary ovarian cancer and 4 physiological ovarian tissue specimens by RT-PCR and western blot analysis. The results were correlated to clinicopathological parameters. Additionally, expression of splicing factors with known involvement in RON alternative splicing regulation was examined. Increased RON levels were detected in all tumor samples (p=0.001) without differences between the primary tumors and metastases. Alternative RON variants were present in the majority of tumor samples (39 of 45; 86.67%). Potential RONΔ165 occurred more often (82.22%) than potential RONΔ160 or RONΔ155 (24.40%). Several significant correlations of RON and splicing factor expression [e.g. ASF/SFRS1 (p=0.035)] were detected. Correlations of RON expression to clinicopathological parameters were not observed. Significant splicing factor interactions (e.g. SRp55/SRp75: p<0.001) were observed in tumor samples with alternative RON splicing. Our data demonstrated upregulated RON isoform expression and significant changes in splicing factor expression in primary ovarian cancer. These findings account for an essential regulatory interplay of splicing factor-driven alterations in the RON alternative splicing pattern with subsequent tumor biological consequences in ovarian cancer.

View Figures

View References

1	Skotheim RI and Nees M: Alternative splicing in cancer: Noise, functional, or systematic? Int J Biochem Cell Biol. 39:1432–1449. 2007. View Article : Google Scholar : PubMed/NCBI
2	Tazi J, Bakkour N and Stamm S: Alternative splicing and disease. Biochim Biophys Acta. 1792:14–26. 2009. View Article : Google Scholar
3	Venables JP: Unbalanced alternative splicing and its significance in cancer. BioEssays. 28:378–386. 2006. View Article : Google Scholar : PubMed/NCBI
4	Huiping C, Kristjansdottir S, Bergthorsson JT, Jonasson JG, Magnusson J, Egilsson V and Ingvarsson S: High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer. 38:728–735. 2002. View Article : Google Scholar : PubMed/NCBI
5	Cheung N, Wong MP, Yuen ST, Leung SY and Chung LP: Tissue-specific expression pattern of vascular endothelial growth factor isoforms in the malignant transformation of lung and colon. Hum Pathol. 29:910–914. 1998. View Article : Google Scholar : PubMed/NCBI
6	Elias AP and Dias S: Microenvironment changes (in pH) affect VEGF alternative splicing. Cancer Microenviron. 1:131–139. 2008. View Article : Google Scholar
7	Hirschfeld M, Jaeger M, Buratti E, Stuani C, Grueneisen J, Gitsch G and Stickeler E: Expression of tumor-promoting Cyr61 is regulated by hTRA2-2401 and acidosis. Hum Mol Genet. 20:2356–2365. 2011. View Article : Google Scholar : PubMed/NCBI
8	Krieg A, Mahotka C, Krieg T, Grabsch H, Müller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE and Gerharz CD: Expression of different survivin variants in gastric carcinomas: First clues to a role of survivin-2b in tumour progression. Br J Cancer. 86:737–743. 2002. View Article : Google Scholar : PubMed/NCBI
9	Vegran F, Boidot R, Oudin C, Riedinger JM and Lizard-Nacol S: Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol. 27:1151–1157. 2005.PubMed/NCBI
10	Eblen ST: Regulation of chemoresistance via alternative messenger RNA splicing. Biochem Pharmacol. 83:1063–1072. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ghigna C, De Toledo M, Bonomi S, Valacca C, Gallo S, Apicella M, Eperon I, Tazi J and Biamonti G: Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: Therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biol. 7:495–503. 2010. View Article : Google Scholar : PubMed/NCBI
12	Collesi C, Santoro MM, Gaudino G and Comoglio PM: A splicing variant of the RON transcript induces constitutive tyrosine kinase activity and an invasive phenotype. Mol Cell Biol. 16:5518–5526. 1996.PubMed/NCBI
13	Lu Y, Yao HP and Wang MH: Multiple variants of the RON receptor tyrosine kinase: Biochemical properties, tumorigenic activities, and potential drug targets. Cancer Lett. 257:157–164. 2007. View Article : Google Scholar : PubMed/NCBI
14	Danilkovitch-Miagkova A: Oncogenic signaling pathways activated by RON receptor tyrosine kinase. Curr Cancer Drug Targets. 3:31–40. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wang MH, Wang D and Chen YQ: Oncogenic and invasive potentials of human macrophage-stimulating protein receptor, the RON receptor tyrosine kinase. Carcinogenesis. 24:1291–1300. 2003. View Article : Google Scholar : PubMed/NCBI
16	Wang MH, Kurtz AL and Chen Y: Identification of a novel splicing product of the RON receptor tyrosine kinase in human colorectal carcinoma cells. Carcinogenesis. 21:1507–1512. 2000. View Article : Google Scholar : PubMed/NCBI
17	Xu XM, Zhou YQ and Wang MH: Mechanisms of cytoplasmic β-catenin accumulation and its involvement in tumorigenic activities mediated by oncogenic splicing variant of the receptor originated from Nantes tyrosine kinase. J Biol Chem. 280:25087–25094. 2005. View Article : Google Scholar : PubMed/NCBI
18	Zhou YQ, He C, Chen YQ, Wang D and Wang MH: Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: Generation of different splicing RON variants and their oncogenic potential. Oncogene. 22:186–197. 2003. View Article : Google Scholar : PubMed/NCBI
19	Lynch HT, Casey MJ, Lynch J, White TE and Godwin AK: Genetics and ovarian carcinoma. Semin Oncol. 25:265–280. 1998.PubMed/NCBI
20	Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zucconi A, Santaguida S, Zannoni G, Scambia G and Ferlini C: Prognostic role of the recepteur d’origine nantais (RON) expression in ovarian cancer patients. Gynecol Oncol. 111:237–243. 2008. View Article : Google Scholar : PubMed/NCBI
21	Prislei S, Mariani M, Raspaglio G, Mozzetti S, Filippetti F, Ferrandina G, Scambia G and Ferlini C: RON and cisplatin resistance in ovarian cancer cell lines. Oncol Res. 19:13–22. 2010. View Article : Google Scholar : PubMed/NCBI
22	Huang Y and Steitz JA: SRprises along a messenger’s journey. Mol Cell. 17:613–615. 2005. View Article : Google Scholar : PubMed/NCBI
23	Zahler AM, Lane WS, Stolk JA and Roth MB: SR proteins: A conserved family of pre-mRNA splicing factors. Genes Dev. 6:837–847. 1992. View Article : Google Scholar : PubMed/NCBI
24	Fischer DC, Noack K, Runnebaum IB, Watermann DO, Kieback DG, Stamm S and Stickeler E: Expression of splicing factors in human ovarian cancer. Oncol Rep. 11:1085–1090. 2004.PubMed/NCBI
25	Stickeler E, Kittrell F, Medina D and Berget SM: Stage-specific changes in SR splicing factors and alternative splicing in mammary tumorigenesis. Oncogene. 18:3574–3582. 1999. View Article : Google Scholar : PubMed/NCBI
26	Fujii T, Seki N, Namoto-Matsubayashi R, Takahashi H, Inoue Y, Toh U, Kage M and Shirouzu K: YB-1 prevents apoptosis via the mTOR/STAT3 pathway in HER-2-overexpressing breast cancer cells. Future Oncol. 5:153–156. 2009. View Article : Google Scholar : PubMed/NCBI
27	Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, Mitsumoto M, Kohno K, Kuwano M and Nakano H: Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer. 85:2450–2454. 1999. View Article : Google Scholar : PubMed/NCBI
28	Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S and Biamonti G: Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20:881–890. 2005. View Article : Google Scholar : PubMed/NCBI
29	Maggiora P, Lorenzato A, Fracchioli S, Costa B, Castagnaro M, Arisio R, Katsaros D, Massobrio M, Comoglio PM and Flavia Di Renzo M: The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp Cell Res. 288:382–389. 2003. View Article : Google Scholar : PubMed/NCBI
30	Wang MH, Yao HP and Zhou YQ: Oncogenesis of RON receptor tyrosine kinase: A molecular target for malignant epithelial cancers. Acta Pharmacol Sin. 27:641–650. 2006. View Article : Google Scholar : PubMed/NCBI
31	Camp ER, Liu W, Fan F, Yang A, Somcio R and Ellis LM: RON, a tyrosine kinase receptor involved in tumor progression and metastasis. Ann Surg Oncol. 12:273–281. 2005. View Article : Google Scholar : PubMed/NCBI
32	Chen YQ, Zhou YQ, Angeloni D, Kurtz AL, Qiang XZ and Wang MH: Overexpression and activation of the RON receptor tyrosine kinase in a panel of human colorectal carcinoma cell lines. Exp Cell Res. 261:229–238. 2000. View Article : Google Scholar : PubMed/NCBI
33	Ma Q, Zhang K, Guin S, Zhou YQ and Wang MH: Deletion or insertion in the first immunoglobulin-plexin-transcription (IPT) domain differentially regulates expression and tumorigenic activities of RON receptor tyrosine kinase. Mol Cancer. 9:3072010. View Article : Google Scholar : PubMed/NCBI